½ÃÀ庸°í¼­
»óǰÄÚµå
1602614

¼¼°èÀÇ ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀå : Á¦Ç° À¯Çü, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Albumin & Creatinine Tests Market by Product (Analyzers, Cartridges, Dipsticks & Kits), Type (Blood & Serum Creatinine Tests, Urine Tests), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 189 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀåÀº 2023³â 14¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 16¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 13.23%·Î ¼ºÀåÇϸç 2030³â¿¡´Â 35¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀåÀÇ ¹üÀ§´Â ½ÅÀå ±â´É ¸ð´ÏÅ͸µ ¹× °ü·Ã Áúȯ Áø´ÜÀÇ ÀÀ¿ë ºÐ¾ß¸¦ Áß½ÉÀ¸·Î Àü°³µË´Ï´Ù.ÀÇ °ËÃâ°ú »ç±¸Ã¼ ¿©°ú·®ÀÇ Æò°¡¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¼ºÀº ´ç´¢º´°ú °íÇ÷¾ÐÀÇ À¯º´·üÀÌ Áõ°¡ÇÏ°í ¼¼°è¿¡¼­ CKDÀÇ ¹ß»ý·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. µµ¿ò°ú ȯÀÚ °á°ú¸¦ °³¼±ÇÕ´Ï´Ù. ÃÖÁ¾ ¿ëµµ´Â Áø´Ü ½ÇÇè½Ç, º´¿ø, Ŭ¸®´Ð µîÀ̸ç, ÀÌ·¯ÇÑ °Ë»ç´Â Á¤±âÀûÀ¸·Î ¼öÇàµÇ´Â ½ÅÀå ±â´É ÆÐ³ÎÀÇ Çʼö ±¸¼º ¿ä¼ÒÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 14¾ï 7,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 16¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 35¾ï 2,000¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 13.23%

ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ¼¼°èÀÇ ¸¸¼º Áúȯ ºÎ´ã Áõ°¡, Áø´Ü ±â¼úÀÇ Áøº¸, Çコ Äɾî ÀÇ½Ä Áõ°¡ µîÀÌ ÀÖ¾î Á¤¹ÐÇϰí Á¶±â Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ºÎÃß±â°í ÀÖ½À´Ï´Ù. µîÀÇ ÃÖ±Ù ±â¼ú Çõ½ÅÀº ´õ ºü¸£°í °£ÆíÇÕ´Ï´Ù. °Ë»ç ¿É¼ÇÀ» Á¦°øÇϰí ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ±â¾÷¿¡°Ô ÀÌ·¯ÇÑ ±âȸ¸¦ Æ÷ÂøÇϱâ À§ÇØ ¼±Áø±¹°ú ½ÅÈï °æÁ¦ ±¹°¡ ¸ðµÎ¸¦ ¼ö¿ë ÇÒ ¼öÀÖ´Â »ç¿ëÀÚ Ä£È­ÀûÀÌ°í ºñ¿ë È¿À²ÀûÀÎ ÈÞ´ë¿ë Àåºñ °³¹ß ¿¡ ÅõÀÚÇØ¾ßÇÕ´Ï´Ù.

±×·¯³ª ±ÔÁ¦»óÀÇ °úÁ¦, °³¹ßµµ»óÁö¿ª¿¡¼­ÀÇ ºñ¿ëÁ¦¾à, ÈÆ·ÃµÈ ÀÎÀçÀÇ Çʿ伺 µîÀÇ Á¦¾àÀº ¿©ÀüÈ÷ Å« Àå¾Ö¹°ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿, °í±Þ Áø´Ü ¹æ¹ý, Â÷º°È­µÈ Á¦Ç° Á¦°øÀ¸·Î À̾îÁö´Â ¿¹Ãø ºÐ¼® °­È­¸¦ À§ÇÑ ÀΰøÁö´É ÅëÇÕ ¿¬±¸¸¦ ÃßÁøÇϰí ÀÖ½À´Ï´Ù.

Çõ½ÅÀÇ Ãø¸é¿¡¼­ ȯÀÚ µ¥ÀÌÅÍ ºÐ¼®¿¡ ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀ» Ȱ¿ëÇϰí, °Ë»ç Á¤È®µµ¸¦ Çâ»ó½Ã۰í, Á¾ÇÕÀûÀÎ ½ÅÀå ÇÁ·ÎÆÄÀÏ ¸µÀ» Á¦°øÇÏ´Â ÅëÇÕ °Ë»ç ¼Ö·ç¼ÇÀ» °³¹ßÇÏ´Â °ÍÀÌ °¡Àå ÁÁÀº ¹æ¹ýÀÔ´Ï´Ù. ÀüüÀûÀ¸·Î, ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀåÀº Àû´çÇÑ °æÀï °ü°è¿¡ ÀÖÀ¸¸ç, ±â¼úÀû Áøº¸³ª Áø´Ü ±â´ÉÀÇ È®Àå¿¡ °­ÇÑ °ü½ÉÀ» °¡Áö¸é¼­ ¹ßÀüÇϰí Àֱ⠶§¹®¿¡ ¼ºÀå¿¡ÀÇ È°±âÂù Àü¸ÁÀÌ ¾à¼ÓµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¾ËºÎ¹Î & Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ȹµæÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼º ½ÅÀå Àå¾Ö Áõ°¡
    • Æ÷ÀÎÆ® ¿Àºê Äɾî(POC) Áø´ÜÀÇ Ã¤¿ë Áõ°¡
    • ¿ä·Î °¨¿°Áõ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ½ºÆý ä´¢¿Í °Ë»ç ¹®Á¦
  • ½ÃÀå ±âȸ
    • ¼Òº¯ °Ë»ç Àü¹ÝÀÇ ÀÚµ¿È­ ½Ã½ºÅÛÀÇ µîÀå
    • º´¸® °Ë»ç½ÇÀÇ ±ÞÁõ¿¡ µû¸¥ °¡Á¤¿ë °Ë»ç ŰƮÀÇ ¼Ò°³
  • ½ÃÀåÀÇ °úÁ¦
    • Áö¹æÀÇ Á¤¹Ðµµ¿Í Á¦ÇÑµÈ ÀÎÇÁ¶ó¿¡ ´ëÇÑ ¿ì·Á

Porter's Five Forces : ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ °¡´ÉÇÕ´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. Æ÷Áö¼Å´× À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù.ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ ÇØÁü¿¡ µû¶ó ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸± Çʿ䰡 ÀÖ½À´Ï´Ù. Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Á¤º¸¸¦ ±â¹ÝÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖ´Â ½Ã½ºÅÛÀ» ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¸¸¼º ½ÅÀå ÁúȯÀÇ ¹ß»ý·ü Áõ°¡
      • Æ÷ÀÎÆ® ¿Àºê Äɾî(POC) Áø´ÜÀÇ Ã¤¿ë Áõ°¡
      • ¿ä·Î °¨¿°Áõ Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • ½ºÆý´¢ »ùÇà äÃë¿Í °Ë»çÀÇ ¹®Á¦Á¡
    • ±âȸ
      • ¼Òº¯ ºÐ¼® Àü¹ÝÀÇ ÀÚµ¿È­ ½Ã½ºÅÛÀÇ ÃâÇö
      • °¡Á¤¿ë °Ë»ç ŰƮÀÇ ÀÎÆ®·Î´ö¼Ç°ú º´¸®ÇÐ ¿¬±¸½Ç¼öÀÇ ±ÞÁõ
    • °úÁ¦
      • Áö¹æÀÇ Á¤¹Ðµµ¿Í ÀÎÇÁ¶óÀÇ ÇѰ迡 ´ëÇÑ ¿ì·Á
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ ½ÃÀå : Á¦Ç°º°

  • ºÐ¼®±â
  • īƮ¸®Áö
    • POC ºÐ¼®±â īƮ¸®Áö
    • Ź»ó ºÐ¼® īƮ¸®Áö
  • µö ½ºÆ½°ú ŰƮ
  • ½Ã¾à

Á¦7Àå ¾ËºÎ¹Î£¦Å©·¹¾ÆÆ¼´Ñ °Ë»ç ½ÃÀå : À¯Çüº°

  • Ç÷¾× ¹× Ç÷û Å©·¹¾ÆÆ¼´Ñ °Ë»ç
  • ¼Òº¯ °Ë»ç
    • ±Û¸®Äھ˺ιΠ°Ë»ç
    • ¼Òº¯ ¾ËºÎ¹Î °Ë»ç
    • ¼Òº¯ Å©·¹¾ÆÆ¼´Ñ °Ë»ç

Á¦8Àå ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Áø´Ü ½ÇÇè½Ç
  • º´¿ø ¹× Ŭ¸®´Ð
  • ¿¬±¸½Ç¡¤¿¬±¸¼Ò

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¾ËºÎ¹Î ¹× Å©·¹¾ÆÆ¼´Ñ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Healthy.io, º£¸µ°Å ÀΰÖÇÏÀÓ°úÀÇ Á¦ÈÞ¸¦ ¹ßÇ¥, ½ÅÀ庴 °Ë»ç¿¡ÀÇ ¾×¼¼½º Çâ»óÀ» ¸ñÇ¥·Î ÇÑ´Ù
    • Healthy.io, ½Ã¸®Áî D ÀÚ±Ý Á¶´Þ·Î 5,000¸¸ ´Þ·¯¸¦ È®º¸
    • American Regent, ÁÖ»ç¿ë Çöʾ×(¾ËºÎ¹Î °áÇÕÇü)¿ë ÆÄŬ¸®Å¹¼¿ ´Ü¹éÁú °áÇÕ ÀÔÀÚ¸¦ ¹ß¸Å
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Abbott Laboratories
  • Abcam PLC
  • Anamol Laboratories Pvt. Ltd.
  • Arbor Assays Inc.
  • ARKRAY, Inc.
  • BTNX Inc.
  • CompareNetworks, Inc.
  • Danaher Corporation
  • Eagle Biosciences, Inc.
  • F. Hoffmann-La Roche AG
  • J. Mitra & Co. Pvt. Ltd.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Ortho Clinical Diagnostics
  • Practo Technologies Private Limited
  • PromoCell GmbH
  • Randox Laboratories Ltd.
  • Siemens AG
  • Sysmex Europe SE
  • Thermo Fisher Scientific Inc.
  • UJIFILM Wako Pure Chemical Corporation
BJH 24.12.11

The Albumin & Creatinine Tests Market was valued at USD 1.47 billion in 2023, expected to reach USD 1.66 billion in 2024, and is projected to grow at a CAGR of 13.23%, to USD 3.52 billion by 2030.

The scope of the albumin and creatinine tests market revolves around their application in monitoring kidney function and diagnosing related disorders. Albumin and creatinine tests are pivotal in evaluating kidney health, particularly for detecting albuminuria and assessing the glomerular filtration rate, which plays a crucial role in managing chronic kidney disease (CKD) and other renal conditions. The necessity for these tests stems from the growing prevalence of diabetes and hypertension, leading to an increased incidence of CKD worldwide. Their application extends to routine health check-ups, aiding early diagnosis and intervention, thus improving patient outcomes. The end-use landscape encompasses diagnostics laboratories, hospitals, and clinics, where these tests are integral components of regular kidney function panels offered.

KEY MARKET STATISTICS
Base Year [2023] USD 1.47 billion
Estimated Year [2024] USD 1.66 billion
Forecast Year [2030] USD 3.52 billion
CAGR (%) 13.23%

Key growth influencers in this market include the rising global burden of chronic diseases, advancements in diagnostic technologies, and increased healthcare awareness, fueling demand for precise and early diagnostic solutions. Recent technological innovations such as point-of-care testing devices present potential opportunities, offering faster and more convenient testing options. For businesses, capturing these opportunities demands investment in developing user-friendly, cost-effective, and portable devices that can cater to both developed and emerging economies.

However, limitations such as regulatory challenges, cost constraints in developing regions, and the need for trained personnel remain significant hurdles. Moreover, an increasing focus on preventive healthcare and personalized medicine drives research into novel biomarkers, sophisticated diagnostic methods, and integration of artificial intelligence for enhanced predictive analytics, which can lead to differentiated product offerings.

In terms of innovation, the best avenues lie in leveraging machine learning algorithms for patient data interpretation, improving test accuracy, and developing integrated testing solutions that offer comprehensive renal profiling. Overall, the market for albumin and creatinine tests is moderately competitive and evolving with a keen interest in technological advancement and expanded diagnostic capabilities, which promises vibrant prospects for growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Albumin & Creatinine Tests Market

The Albumin & Creatinine Tests Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of chronic kidney disorders
    • Rising adoption of point-of-care (POC) diagnostics
    • Growing cases of urinary tract infections
  • Market Restraints
    • Problems with spot urine sampling and testing
  • Market Opportunities
    • Emergence of automated systems for overall urine analysis
    • Introduction of home testing kit coupled with surge in number of pathology laboratory
  • Market Challenges
    • Concern with the accuracy and limited infrastructure in rural areas

Porter's Five Forces: A Strategic Tool for Navigating the Albumin & Creatinine Tests Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Albumin & Creatinine Tests Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Albumin & Creatinine Tests Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Albumin & Creatinine Tests Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Albumin & Creatinine Tests Market

A detailed market share analysis in the Albumin & Creatinine Tests Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Albumin & Creatinine Tests Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Albumin & Creatinine Tests Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Albumin & Creatinine Tests Market

A strategic analysis of the Albumin & Creatinine Tests Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Albumin & Creatinine Tests Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam PLC, Anamol Laboratories Pvt. Ltd., Arbor Assays Inc., ARKRAY, Inc., BTNX Inc., CompareNetworks, Inc., Danaher Corporation, Eagle Biosciences, Inc., F. Hoffmann-La Roche AG, J. Mitra & Co. Pvt. Ltd., Laboratory Corporation of America Holdings, Merck KGaA, Ortho Clinical Diagnostics, Practo Technologies Private Limited, PromoCell GmbH, Randox Laboratories Ltd., Siemens AG, Sysmex Europe SE, Thermo Fisher Scientific Inc., and UJIFILM Wako Pure Chemical Corporation.

Market Segmentation & Coverage

This research report categorizes the Albumin & Creatinine Tests Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Analyzers, Cartridges, Dipsticks & Kits, and Reagents. The Cartridges is further studied across POC Analyzer Cartridges and Table-top Analyzer Cartridges.
  • Based on Type, market is studied across Blood & Serum Creatinine Tests and Urine Tests. The Urine Tests is further studied across Glycated Albumin Tests, Urine Albumin Tests, and Urine Creatinine Tests.
  • Based on End User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Laboratories & Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of chronic kidney disorders
      • 5.1.1.2. Rising adoption of point-of-care (POC) diagnostics
      • 5.1.1.3. Growing cases of urinary tract infections
    • 5.1.2. Restraints
      • 5.1.2.1. Problems with spot urine sampling and testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of automated systems for overall urine analysis
      • 5.1.3.2. Introduction of home testing kit coupled with surge in number of pathology laboratory
    • 5.1.4. Challenges
      • 5.1.4.1. Concern with the accuracy and limited infrastructure in rural areas
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Albumin & Creatinine Tests Market, by Product

  • 6.1. Introduction
  • 6.2. Analyzers
  • 6.3. Cartridges
    • 6.3.1. POC Analyzer Cartridges
    • 6.3.2. Table-top Analyzer Cartridges
  • 6.4. Dipsticks & Kits
  • 6.5. Reagents

7. Albumin & Creatinine Tests Market, by Type

  • 7.1. Introduction
  • 7.2. Blood & Serum Creatinine Tests
  • 7.3. Urine Tests
    • 7.3.1. Glycated Albumin Tests
    • 7.3.2. Urine Albumin Tests
    • 7.3.3. Urine Creatinine Tests

8. Albumin & Creatinine Tests Market, by End User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals & Clinics
  • 8.4. Research Laboratories & Institutes

9. Americas Albumin & Creatinine Tests Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Albumin & Creatinine Tests Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Albumin & Creatinine Tests Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Healthy.io Announces Collaboration with Boehringer Ingelheim to Increase Access to Testing for Kidney Disease
    • 12.3.2. Healthy.io Secures USD 50 Million in Series D Funding
    • 12.3.3. American Regent Launches Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Abcam PLC
  • 3. Anamol Laboratories Pvt. Ltd.
  • 4. Arbor Assays Inc.
  • 5. ARKRAY, Inc.
  • 6. BTNX Inc.
  • 7. CompareNetworks, Inc.
  • 8. Danaher Corporation
  • 9. Eagle Biosciences, Inc.
  • 10. F. Hoffmann-La Roche AG
  • 11. J. Mitra & Co. Pvt. Ltd.
  • 12. Laboratory Corporation of America Holdings
  • 13. Merck KGaA
  • 14. Ortho Clinical Diagnostics
  • 15. Practo Technologies Private Limited
  • 16. PromoCell GmbH
  • 17. Randox Laboratories Ltd.
  • 18. Siemens AG
  • 19. Sysmex Europe SE
  • 20. Thermo Fisher Scientific Inc.
  • 21. UJIFILM Wako Pure Chemical Corporation
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦